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Patients with implanted cardioverter-defibrillator (ICD) of-
ten have justified ICD activations no matter if the indica-
tion for implantation was primary or secondary prophy-
laxis of sudden death. First line therapy in the prevention 
of recidivate ventricular arrhythmia in these patients is an-
tiarrhythmic therapy, but if this is inefficient, arrhythmic 
substrate radiofrequency (RF) ablation is recommended. 
Ablation treatment is an accepted procedure in patients 
with ischemic heart disease, but it has rarely been used in 
patients with idiopathic and particularly polymorphic ven-
tricular tachycardia (VT). It must be emphasized that acute 
ablation is relatively successful, but because of substrates 
progression, relapses of VTs are very frequent (35%) (1). 
Therefore, antiarrhythmic therapy remains an important 
therapy after the ICD implantation, before, and often after 
RF ablation (2).
We present the cases of five patients in whom the preven-
tion of recidivate VTs was achieved only by an old nonselec-
tive beta-blocker propranolol (dose 20 × 40 or 2 × 80mg).
Patient 1: a 52 years old woman with ICD implanted as a 
secondary prevention after out-of-hospital cardiac arrest 
caused by ventricular fibrillation. There was no structural 
heart disease, coronarography was normal, and there was 
only arterial hypertension in patient’s history. QTc interval 
was within the reference range, there were no Brugada 
syndrome elements, and no sudden death in family his-
tory. During the first year after the implantation, ICD was 
activated for more than 10 times because of polymorphic 
VT in spite of medicaments therapy. On one occasion even 
an electrical storm occurred. After the implantation, biso-
prolol maximum dose was given, later in combination with 
mexiletine, which was stopped as a result of intolerance. 
Combination with amiodarone was used for a short period 
of time but with no effects. Only after bisoprolol had been 
replaced with propranolol, there were no tachycardias and 
ICD stopped activating. Since then the patient has been 
followed-up for 5 years.
Patient 2: a 56 years old man with no family or individual 
heart disease history, or any other serious disease. ICD was 
implanted as secondary prophylaxis after relapsing synco-
pes caused by VTs. The first therapy with amiodarone had 
not prevented multiple ICD activations, so it was replaced 
by a combination of bisoprolol and mexiletine. Despite 
the new therapy, ICD continued to activate for several jus-
tified occasions (5 times). Only after bisoprolol had been 
replaced with propranolol, ICD stopped activating. Since 
then the patient has been followed-up for 3 years. In the 
meantime, mexiletine therapy has been stopped (it is un-
available in Croatia), so now he takes propranolol only.
Patient 3: a 69 years old man with ICD implanted after re-
lapsing sustained VTs. The patient had no structural heart 
disease or any signs of ischemia. Coronarography was nor-
mal. In spite of the maximum dose of bisoprolol in combi-
nation with amiodarone, ICD was reasonably activated on 
over 20 occasions. On 3 occasions, an electrical storm was 
detected. Arrhythmia could not have been controlled even 
by the combination of bisoprolol and mexiletine. Only the 
replacement of bisoprolol by propranolol led to a com-
plete VT suppression. In the last 3 years, the patient has 
not had any ICD activation. In the meantime, mexiletine 
therapy has been stopped.
Patient 4: a 86 years old man. Two years ago, he had 
inferioposterior myocardial infarction with ST-eleva-
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tion (STEMI) and a year after he was hospitalized for hemo-
dynamically unstable VT. Slightly reduced ejection fraction 
(EF 45%-50%) was determined, caused by inferioposterior 
hypokinesia. Coronarography showed an old collateralized 
occlusion of the right coronary artery (RCA) and irrelevant 
changes on other coronary arteries. Sustained VTs repeat-
ed daily, despite the use of different antiarrhythmics: biso-
prolol, lidocaine, amiodarone, and magnesium. After the 
temporary electrode had been placed, conversion was 
achieved by overdrive electrostimulation, but only occa-
sionally. However, electrical cardioversion had to be done 
in most cases (6 times). Only the combination of propra-
nolol and lidocaine in high doses managed to suppress VT. 
The patient had a successful RF ablation of VT with propra-
nolol therapy only. During the 2 years of follow-up, he has 
had no arrhythmia. ICD has not been implanted.
Patient 5: a 60 years old man. After anteroseptal STEMI with 
severely reduced left ventricular systolic function, the pa-
tient developed frequent VTs that responded neither to 
combination of bisoprolol and lidocaine nor to overdrive 
stimulation. The use of amiodarone induced a remarkable 
extension of the QTc interval without suppressing arrhyth-
mia. On most occasions, arrhythmia had to be stopped 
by electrical cardioversion (5 times). Only after using pro-
pranolol instead of bisoprolol, arrhythmia was completely 
suppressed. When propranolol had been cancelled, be-
cause of septic shock, VT relapsed. After the septic shock 
had been stabilized, ICD was implanted and propranolol 
was included to the therapy again. Further follow-up (1 
year) has not recorded any ICD activation.
In our cases, non-selective propranolol was more effective 
in suppressing severe VTs than newer selective beta block-
er bisoprolol. Unlike bisoprolol, propranolol blocks both 
beta 1 and beta 2 receptors (20% of beta adrenergic re-
ceptors in the heart) and owing to liposolubility also pen-
etrates into the brain (3). Thereby, it can also result in the 
central inhibition of the sympathetic nervous system. The 
unique stability effect on the membrane of myocytes has 
also been described (4). Previous studies showed that pro-
pranolol in combination with amiodarone offered the best 
prevention of VT relapses (5). The reason why propranolol 
is not widely used in patients with cardiomyopathy is the 
lack of evidence-based data for these indications. Studies 
in patients with cardiomyopathy have recently been con-
ducted using only newer beta-blockers (carvedilol, meto-
prolol, bisoprolol) (6). We believe it could be useful to con-
duct a study on propranolol, because propranolol possibly 
has more beneficial effect on the survival of patients with 
cardiomyopathy than selective beta blockers.
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